EcoDrugPlus

Mitogen-Activated Protein Kinase 3

Ensembl ID : ENSEEEG00000001594
Gene Symbol: MAPK3
4 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase 8a

Ensembl ID : ENSEEEG00000001743
Gene Symbol: MAPK8A
4 Cross references
222 Possible Orthologues:

Mitogen-Activated Protein Kinase 8b

Ensembl ID : ENSEEEG00000002902
Gene Symbol: MAPK8B
4 Cross references
223 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSEEEG00000022402
Gene Symbol: MAP2K1
4 Cross references
215 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2a

Ensembl ID : ENSEEEG00000013748
Gene Symbol: MAP2K2A
2 Cross references
218 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2b

Ensembl ID : ENSEEEG00000016135
Gene Symbol: MAP2K2B
4 Cross references
202 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 1

Ensembl ID : ENSEEEG00000020908
Gene Symbol: MAP3K1
2 Cross references
160 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSEEEG00000015820
Gene Symbol: MAP3K10
2 Cross references
183 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSEEEG00000014212
Gene Symbol: MAP3K12
4 Cross references
191 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSEEEG00000009701
Gene Symbol: MAP3K12
2 Cross references
184 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSEEEG00000020470
Gene Symbol: MAP3K13
4 Cross references
201 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSEEEG00000022307
Gene Symbol: MAP3K5
4 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).